Our results propose ATR as a promising target in bladder cancer by (1) enhancing radio-sensitivity through classical ATR inhibition and (2) exploiting resistant ATRi-adaptation as a vulnerability by targeting compensatory HR repair reliance through RAD51 inhibition. The gene discussed is RAD51; the disease is urinary bladder carcinoma.